Skip to main content

Myelodysplastic Syndromes (MDS): Diagnosis, Treatment and Side Effects Management

Recorded on April 14, 2020

Click Here to Participate 

Format: Recorded Webinar
1.0 CE Credit Available Until: June 30, 2021

 

Target Audience

Nurse practitioners, nurses and oncology social workers involved in the care of patients with myelodysplastic syndromes (MDS)

Course Content Level for Social Workers: Intermediate and Advanced
 

Description

This webinar will provide a basic overview of myelodysplastic syndromes (MDS): focusing on strategies for diagnosis and patient management. Risk assessment, treatment options, the role of various members of the healthcare team in addressing treatment goals, guidance for patients and caregivers in treatment decision making, as well as resources for patients, caregivers and healthcare providers will be discussed.
 

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe the various types and subtypes of MDS
  • Identify tests used to diagnose disease and monitor treatment of MDS
  • Explain the overarching goals of treatment for the types of MDS
  • Explain approved and emerging treatment option for MDS, including stem cell transplantation, and the role of clinical trials
  • Describe the roles of the pharmacist, the nurse, and the social worker in treating patients with MDS

 

Faculty

Sangmin Lee, MD
Assistant Professor of Medicine
Weill Cornell Medical College 
Assistant Attending Physician
New York-Presbyterian Hospital
New York, NY

Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager
Hematology/Oncology
Columbia University Irving Medical Center
New York, NY

Ayelet Nelson, MSW, ANP-BC
Leukemia Outpatient Nurse Practitioner
Weill Cornell Medicine
New York, NY


Continuing Education

This activity is approved for 1.0 contact hour of continuing education (which includes .75 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20064277. This activity was planned in accordance with AANP Accreditation Standards and Policies.

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing.

The Leukemia & Lymphoma Society (LLS)Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/17-12/14/2020. Social workers completing this course receive 1.0  continuing education credit.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hours for this activity.

Participants must attend the free webinar in its entirety, submit the online evaluation form, and complete and submit the online post-test with a passing score of 70% to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.


 

Providers

This program is provided by The Leukemia & Lymphoma Society.

 

Click Here to Participate

Participants gain access to the webinar via the registration button above.

To view system requirements please visit https://llsce.org/system-requirements.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at infocenter@LLS.org.

 



< Back to Continuing Education